# doc_id = 8931701
Identification	0	14	O
of	15	17	O
WASP	18	22	O
mutations	23	32	O
,	32	33	O
mutation	34	42	O
hotspots	43	51	O
and	52	55	O
genotype	56	64	O
-	64	65	O
phenotype	65	74	O
disparities	75	86	O
in	87	89	O
24	90	92	O
patients	93	101	O
with	102	106	O
the	107	110	O
Wiskott	111	118	B-SpecificDisease
-	118	119	I-SpecificDisease
Aldrich	119	126	I-SpecificDisease
syndrome	127	135	E-SpecificDisease
.	135	136	O

The	137	140	O
Wiskott	141	148	B-SpecificDisease
-	148	149	I-SpecificDisease
Aldrich	149	156	I-SpecificDisease
syndrome	157	165	E-SpecificDisease
(	166	167	O
WAS	167	170	S-SpecificDisease
),	170	172	O
an	173	175	O
X	176	177	B-DiseaseClass
-	177	178	I-DiseaseClass
linked	178	184	I-DiseaseClass
immunodeficiency	185	201	I-DiseaseClass
disease	202	209	E-DiseaseClass
caused	210	216	O
by	217	219	O
mutation	220	228	O
in	229	231	O
the	232	235	O
recently	236	244	O
isolated	245	253	O
gene	254	258	O
encoding	259	267	O
WAS	268	271	S-Modifier
protein	272	279	O
(	280	281	O
WASP	281	285	O
),	285	287	O
is	288	290	O
known	291	296	O
to	297	299	O
be	300	302	O
associated	303	313	O
with	314	318	O
extensive	319	328	O
clinical	329	337	O
heterogeneity	338	351	O
.	351	352	O

Cumulative	353	363	O
mutation	364	372	O
data	373	377	O
have	378	382	O
revealed	383	391	O
that	392	396	O
WASP	397	401	O
genotypes	402	411	O
are	412	415	O
also	416	420	O
highly	421	427	O
variable	428	436	O
among	437	442	O
WAS	443	446	S-Modifier
patients	447	455	O
,	455	456	O
but	457	460	O
the	461	464	O
relationship	465	477	O
of	478	480	O
phenotype	481	490	O
with	491	495	O
genotype	496	504	O
in	505	507	O
this	508	512	O
disease	513	520	O
remains	521	528	O
unclear	529	536	O
.	536	537	O

To	538	540	O
address	541	548	O
this	549	553	O
issue	554	559	O
we	560	562	O
characterized	563	576	O
WASP	577	581	O
mutations	582	591	O
in	592	594	O
24	595	597	O
unrelated	598	607	O
WAS	608	611	S-Modifier
patients	612	620	O
,	620	621	O
including	622	631	O
18	632	634	O
boys	635	639	O
with	640	644	O
severe	645	651	O
classical	652	661	O
WAS	662	665	S-SpecificDisease
and	666	669	O
6	670	671	O
boys	672	676	O
expressing	677	687	O
mild	688	692	O
forms	693	698	O
of	699	701	O
the	702	705	O
disease	706	713	O
,	713	714	O
and	715	718	O
then	719	723	O
examined	724	732	O
the	733	736	O
degree	737	743	O
of	744	746	O
correlation	747	758	O
of	759	761	O
these	762	767	O
as	768	770	O
well	771	775	O
as	776	778	O
all	779	782	O
previously	783	793	O
published	794	803	O
WASP	804	808	O
mutations	809	818	O
with	819	823	O
disease	824	831	O
severity	832	840	O
.	840	841	O

By	842	844	O
analysis	845	853	O
of	854	856	O
these	857	862	O
compiled	863	871	O
mutation	872	880	O
data	881	885	O
,	885	886	O
we	887	889	O
demonstrated	890	902	O
clustering	903	913	O
of	914	916	O
WASP	917	921	O
mutations	922	931	O
within	932	938	O
the	939	942	O
four	943	947	O
most	948	952	O
N	953	954	O
-	954	955	O
terminal	955	963	O
exons	964	969	O
of	970	972	O
the	973	976	O
gene	977	981	O
and	982	985	O
also	986	990	O
identified	991	1001	O
several	1002	1009	O
sites	1010	1015	O
within	1016	1022	O
this	1023	1027	O
region	1028	1034	O
as	1035	1037	O
hotspots	1038	1046	O
for	1047	1050	O
WASP	1051	1055	O
mutation	1056	1064	O
.	1064	1065	O

These	1066	1071	O
characteristics	1072	1087	O
were	1088	1092	O
observed	1093	1101	O
,	1101	1102	O
however	1103	1110	O
,	1110	1111	O
in	1112	1114	O
both	1115	1119	O
severe	1120	1126	O
and	1127	1130	O
mild	1131	1135	O
cases	1136	1141	O
of	1142	1144	O
the	1145	1148	O
disease	1149	1156	O
.	1156	1157	O

Similarly	1158	1167	O
,	1167	1168	O
while	1169	1174	O
the	1175	1178	O
cumulative	1179	1189	O
data	1190	1194	O
revealed	1195	1203	O
a	1204	1205	O
predominance	1206	1218	O
of	1219	1221	O
missense	1222	1230	O
mutations	1231	1240	O
among	1241	1246	O
the	1247	1250	O
WASP	1251	1255	O
gene	1256	1260	O
lesions	1261	1268	O
observed	1269	1277	O
in	1278	1280	O
boys	1281	1285	O
with	1286	1290	O
isolated	1291	1299	B-SpecificDisease
thrombocytopenia	1300	1316	E-SpecificDisease
,	1316	1317	O
missense	1318	1326	O
mutations	1327	1336	O
were	1337	1341	O
not	1342	1345	O
exclusively	1346	1357	O
associated	1358	1368	O
with	1369	1373	O
milder	1374	1380	O
WAS	1381	1384	S-Modifier
phenotypes	1385	1395	O
,	1395	1396	O
but	1397	1400	O
also	1401	1405	O
comprised	1406	1415	O
a	1416	1417	O
substantial	1418	1429	O
portion	1430	1437	O
(	1438	1439	O
38	1439	1441	O
%)	1441	1443	O
of	1444	1446	O
the	1447	1450	O
WASP	1451	1455	O
gene	1456	1460	O
defects	1461	1468	O
found	1469	1474	O
in	1475	1477	O
patients	1478	1486	O
with	1487	1491	O
severe	1492	1498	O
disease	1499	1506	O
.	1506	1507	O

These	1508	1513	O
findings	1514	1522	O
,	1522	1523	O
as	1524	1526	O
well	1527	1531	O
as	1532	1534	O
the	1535	1538	O
detection	1539	1548	O
of	1549	1551	O
identical	1552	1561	O
WASP	1562	1566	O
mutations	1567	1576	O
in	1577	1579	O
patients	1580	1588	O
with	1589	1593	O
disparate	1594	1603	O
phenotypes	1604	1614	O
,	1614	1615	O
reveal	1616	1622	O
a	1623	1624	O
lack	1625	1629	O
of	1630	1632	O
phenotype	1633	1642	O
concordance	1643	1654	O
with	1655	1659	O
genotype	1660	1668	O
in	1669	1671	O
WAS	1672	1675	S-SpecificDisease
and	1676	1679	O
thus	1680	1684	O
imply	1685	1690	O
that	1691	1695	O
phenotypic	1696	1706	O
outcome	1707	1714	O
in	1715	1717	O
this	1718	1722	O
disease	1723	1730	O
cannot	1731	1737	O
be	1738	1740	O
reliably	1741	1749	O
predicted	1750	1759	O
solely	1760	1766	O
on	1767	1769	O
the	1770	1773	O
basis	1774	1779	O
of	1780	1782	O
WASP	1783	1787	O
genotypes	1788	1797	O
.	1797	1798	O

# doc_id = 9174057
Mutations	0	9	O
in	10	12	O
the	13	16	O
arginine	17	25	O
-	25	26	O
rich	26	30	O
protein	31	38	O
gene	39	43	O
(	44	45	O
ARP	45	48	O
)	48	49	O
in	50	52	O
pancreatic	53	63	B-SpecificDisease
cancer	64	70	E-SpecificDisease
.	70	71	O

The	72	75	O
ARP	76	79	O
gene	80	84	O
encodes	85	92	O
a	93	94	O
highly	95	101	O
conserved	102	111	O
arginine	112	120	O
-	120	121	O
rich	121	125	O
protein	126	133	O
from	134	138	O
chromosomal	139	150	O
band	151	155	O
3p21	156	160	O
.	160	161	O
1	161	162	O
.	162	163	O

At	164	166	O
the	167	170	O
cytogenetic	171	182	O
level	183	188	O
this	189	193	O
region	194	200	O
is	201	203	O
frequently	204	214	O
deleted	215	222	O
in	223	225	O
a	226	227	O
variety	228	235	O
of	236	238	O
different	239	248	O
solid	249	254	B-DiseaseClass
tumors	255	261	E-DiseaseClass
,	261	262	O
although	263	271	O
not	272	275	O
in	276	278	O
pancreatic	279	289	B-SpecificDisease
cancer	290	296	E-SpecificDisease
.	296	297	O

We	298	300	O
have	301	305	O
reported	306	314	O
the	315	318	O
presence	319	327	O
of	328	330	O
a	331	332	O
specific	333	341	O
mutation	342	350	O
(	351	352	O
ATG50	352	357	O
-->	357	360	O
AGG	360	363	O
)	363	364	O
or	365	367	O
deletion	368	376	O
of	377	379	O
codon	380	385	O
50	386	388	O
of	389	391	O
the	392	395	O
ARP	396	399	O
gene	400	404	O
in	405	407	O
different	408	417	O
tumor	418	423	B-DiseaseClass
types	424	429	E-DiseaseClass
(	430	431	O
Shridhar	431	439	O
et	440	442	O
al	443	445	O
.,	445	447	O
1996	448	452	O
,	452	453	O
1996a	454	459	O
).	459	461	O

In	462	464	O
the	465	468	O
present	469	476	O
study	477	482	O
,	482	483	O
we	484	486	O
have	487	491	O
observed	492	500	O
mutations	501	510	O
involving	511	520	O
codon	521	526	O
50	527	529	O
in	530	532	O
11	533	535	O
of	536	538	O
37	539	541	O
pancreatic	542	552	B-SpecificDisease
tumors	553	559	E-SpecificDisease
.	559	560	O

The	561	564	O
frequency	565	574	O
of	575	577	O
codon	578	583	O
50	584	586	O
mutation	587	595	O
is	596	598	O
roughly	599	606	O
the	607	610	O
same	611	615	O
in	616	618	O
pancreatic	619	629	B-SpecificDisease
tumors	630	636	E-SpecificDisease
as	637	639	O
in	640	642	O
the	643	646	O
other	647	652	O
types	653	658	O
of	659	661	O
tumors	662	668	S-DiseaseClass
previously	669	679	O
examined	680	688	O
.	688	689	O

In	690	692	O
addition	693	701	O
,	701	702	O
we	703	705	O
have	706	710	O
detected	711	719	O
mutations	720	729	O
at	730	732	O
codon	733	738	O
51	739	741	O
in	742	744	O
multiple	745	753	O
PCR	754	757	O
subclones	758	767	O
in	768	770	O
two	771	774	O
other	775	780	O
pancreatic	781	791	B-SpecificDisease
tumors	792	798	E-SpecificDisease
.	798	799	O

Mutations	800	809	O
in	810	812	O
the	813	816	O
ARP	817	820	O
gene	821	825	O
are	826	829	O
thus	830	834	O
commonly	835	843	O
observed	844	852	O
in	853	855	O
pancreatic	856	866	B-SpecificDisease
cancer	867	873	E-SpecificDisease
,	873	874	O
as	875	877	O
well	878	882	O
as	883	885	O
many	886	890	O
other	891	896	O
cancers	897	904	S-DiseaseClass
.	904	905	O

# doc_id = 9056547
Nonsense	0	8	O
mutation	9	17	O
in	18	20	O
exon	21	25	O
3	26	27	O
of	28	30	O
the	31	34	O
proteolipid	35	46	O
protein	47	54	O
gene	55	59	O
(	60	61	O
PLP	61	64	O
)	64	65	O
in	66	68	O
a	69	70	O
family	71	77	O
with	78	82	O
an	83	85	O
unusual	86	93	O
form	94	98	O
of	99	101	O
Pelizaeus	102	111	B-SpecificDisease
-	111	112	I-SpecificDisease
Merzbacher	112	122	I-SpecificDisease
disease	123	130	E-SpecificDisease
.	130	131	O

We	132	134	O
report	135	141	O
a	142	143	O
G	144	145	O
-->	145	148	O
A	148	149	O
transition	150	160	O
at	161	163	O
nucleotide	164	174	O
431	175	178	O
of	179	181	O
the	182	185	O
proteolipid	186	197	O
protein	198	205	O
gene	206	210	O
(	211	212	O
PLP	212	215	O
)	215	216	O
results	217	224	O
in	225	227	O
a	228	229	O
nonsense	230	238	O
codon	239	244	O
in	245	247	O
a	248	249	O
family	250	256	O
with	257	261	O
an	262	264	O
unusual	265	272	O
form	273	277	O
of	278	280	O
Pelizaeus	281	290	B-SpecificDisease
-	290	291	I-SpecificDisease
Merzbacher	291	301	I-SpecificDisease
disease	302	309	E-SpecificDisease
(	310	311	O
PMD	311	314	S-SpecificDisease
).	314	316	O

The	317	320	O
mutation	321	329	O
,	329	330	O
which	331	336	O
creates	337	344	O
a	345	346	O
second	347	353	O
AluI	354	358	O
restriction	359	370	O
site	371	375	O
,	375	376	O
results	377	384	O
in	385	387	O
a	388	389	O
nonsense	390	398	O
mutation	399	407	O
in	408	410	O
PLP	411	414	O
.	414	415	O

The	416	419	O
clinical	420	428	O
picture	429	436	O
resembles	437	446	O
somewhat	447	455	O
that	456	460	O
of	461	463	O
X	464	465	B-SpecificDisease
-	465	466	I-SpecificDisease
linked	466	472	I-SpecificDisease
spastic	473	480	I-SpecificDisease
paraplegia	481	491	E-SpecificDisease
(	492	493	O
SPG	493	496	S-SpecificDisease
).	496	498	O

It	499	501	O
differs	502	509	O
from	510	514	O
this	515	519	O
and	520	523	O
both	524	528	O
the	529	532	O
classical	533	542	O
and	543	546	O
connatal	547	555	O
forms	556	561	O
of	562	564	O
PMD	565	568	S-SpecificDisease
in	569	571	O
that	572	576	O
it	577	579	O
is	580	582	O
relatively	583	593	O
mild	594	598	O
in	599	601	O
form	602	606	O
,	606	607	O
onset	608	613	O
is	614	616	O
delayed	617	624	O
beyond	625	631	O
age	632	635	O
2	636	637	O
years	638	643	O
,	643	644	O
nystagmus	645	654	S-DiseaseClass
is	655	657	O
absent	658	664	O
,	664	665	O
tremors	666	673	S-DiseaseClass
are	674	677	O
prominent	678	687	O
,	687	688	O
mental	689	695	B-DiseaseClass
retardation	696	707	E-DiseaseClass
is	708	710	O
not	711	714	O
severe	715	721	O
,	721	722	O
some	723	727	O
patients	728	736	O
show	737	741	O
dementia	742	750	S-DiseaseClass
or	751	753	O
personality	754	765	B-DiseaseClass
disorders	766	775	E-DiseaseClass
,	775	776	O
the	777	780	O
disease	781	788	O
is	789	791	O
progressive	792	803	O
rather	804	810	O
than	811	815	O
static	816	822	O
in	823	825	O
some	826	830	O
,	830	831	O
and	832	835	O
several	836	843	O
females	844	851	O
show	852	856	O
signs	857	862	O
of	863	865	O
disease	866	873	O
.	873	874	O

The	875	878	O
nonsense	879	887	O
mutation	888	896	O
,	896	897	O
which	898	903	O
is	904	906	O
in	907	909	O
exon	910	914	O
3B	915	917	O
,	917	918	O
should	919	925	O
block	926	931	O
the	932	935	O
synthesis	936	945	O
of	946	948	O
normal	949	955	O
PLP	956	959	O
but	960	963	O
spare	964	969	O
DM20	970	974	O
,	974	975	O
the	976	979	O
isoform	980	987	O
whose	988	993	O
persistence	994	1005	O
has	1006	1009	O
been	1010	1014	O
associated	1015	1025	O
with	1026	1030	O
mild	1031	1035	O
forms	1036	1041	O
of	1042	1044	O
PLP	1045	1048	B-DiseaseClass
-	1048	1049	I-DiseaseClass
associated	1049	1059	I-DiseaseClass
disease	1060	1067	E-DiseaseClass
in	1068	1070	O
both	1071	1075	O
humans	1076	1082	O
and	1083	1086	O
mice	1087	1091	O
.	1091	1092	O

# doc_id = 8790412
The	0	3	O
hybrid	4	10	O
PAX3	11	15	O
-	15	16	O
FKHR	16	20	O
fusion	21	27	O
protein	28	35	O
of	36	38	O
alveolar	39	47	B-SpecificDisease
rhabdomyosarcoma	48	64	E-SpecificDisease
transforms	65	75	O
fibroblasts	76	87	O
in	88	90	O
culture	91	98	O
.	98	99	O

Pediatric	100	109	B-SpecificDisease
alveolar	110	118	I-SpecificDisease
rhabdomyosarcoma	119	135	E-SpecificDisease
is	136	138	O
characterized	139	152	O
by	153	155	O
a	156	157	O
chromosomal	158	169	O
translocation	170	183	O
that	184	188	O
fuses	189	194	O
parts	195	200	O
of	201	203	O
the	204	207	O
PAX3	208	212	O
and	213	216	O
FKHR	217	221	O
genes	222	227	O
.	227	228	O

PAX3	229	233	O
codes	234	239	O
for	240	243	O
a	244	245	O
transcriptional	246	261	O
regulator	262	271	O
that	272	276	O
controls	277	285	O
developmental	286	299	O
programs	300	308	O
,	308	309	O
and	310	313	O
FKHR	314	318	O
codes	319	324	O
for	325	328	O
a	329	330	O
forkhead	331	339	O
-	339	340	O
winged	340	346	O
helix	347	352	O
protein	353	360	O
,	360	361	O
also	362	366	O
a	367	368	O
likely	369	375	O
transcription	376	389	O
factor	390	396	O
.	396	397	O

The	398	401	O
PAX3	402	406	O
-	406	407	O
FKHR	407	411	O
fusion	412	418	O
product	419	426	O
retains	427	434	O
the	435	438	O
DNA	439	442	O
binding	443	450	O
domains	451	458	O
of	459	461	O
the	462	465	O
PAX3	466	470	O
protein	471	478	O
and	479	482	O
the	483	486	O
putative	487	495	O
activator	496	505	O
domain	506	512	O
of	513	515	O
the	516	519	O
FKHR	520	524	O
protein	525	532	O
.	532	533	O

The	534	537	O
PAX3	538	542	O
-	542	543	O
FKHR	543	547	O
protein	548	555	O
has	556	559	O
been	560	564	O
shown	565	570	O
to	571	573	O
function	574	582	O
as	583	585	O
a	586	587	O
transcriptional	588	603	O
activator	604	613	O
.	613	614	O

Using	615	620	O
the	621	624	O
RCAS	625	629	O
retroviral	630	640	O
vector	641	647	O
,	647	648	O
we	649	651	O
have	652	656	O
introduced	657	667	O
the	668	671	O
PAX3	672	676	O
-	676	677	O
FKHR	677	681	O
gene	682	686	O
into	687	691	O
chicken	692	699	O
embryo	700	706	O
fibroblasts	707	718	O
.	718	719	O

Expression	720	730	O
of	731	733	O
the	734	737	O
PAX3	738	742	O
-	742	743	O
FKHR	743	747	O
protein	748	755	O
in	756	758	O
these	759	764	O
cells	765	770	O
leads	771	776	O
to	777	779	O
transformation	780	794	O
:	794	795	O
the	796	799	O
cells	800	805	O
become	806	812	O
enlarged	813	821	O
,	821	822	O
grow	823	827	O
tightly	828	835	O
packed	836	842	O
and	843	846	O
in	847	849	O
multiple	850	858	O
layers	859	865	O
,	865	866	O
and	867	870	O
acquire	871	878	O
the	879	882	O
ability	883	890	O
for	891	894	O
anchorage	895	904	O
-	904	905	O
independent	905	916	O
growth	917	923	O
.	923	924	O

This	925	929	O
cellular	930	938	O
transformation	939	953	O
in	954	956	O
vitro	957	962	O
will	963	967	O
facilitate	968	978	O
studies	979	986	O
on	987	989	O
the	990	993	O
mechanism	994	1003	O
of	1004	1006	O
PAX3	1007	1011	O
-	1011	1012	O
FKHR	1012	1016	O
-	1016	1017	O
induced	1017	1024	O
oncogenesis	1025	1036	O
.	1036	1037	O

# doc_id = 8786135
Comparative	0	11	O
genome	12	18	O
mapping	19	26	O
of	27	29	O
the	30	33	O
ataxia	34	40	B-Modifier
-	40	41	I-Modifier
telangiectasia	41	55	E-Modifier
region	56	62	O
in	63	65	O
mouse	66	71	O
,	71	72	O
rat	73	76	O
,	76	77	O
and	78	81	O
Syrian	82	88	O
hamster	89	96	O
.	96	97	O

Chromosomal	98	109	O
locations	110	119	O
of	120	122	O
the	123	126	O
Atm	127	130	O
(	131	132	O
ataxia	132	138	B-Modifier
-	138	139	I-Modifier
telangiectasia	139	153	E-Modifier
(	154	155	O
AT	155	157	S-Modifier
)-	157	159	O
mutated	159	166	O
)	166	167	O
and	168	171	O
Acat1	172	177	O
(	178	179	O
mitochondrial	179	192	O
acetoacetyl	193	204	O
-	204	205	O
CoA	205	208	O
thiolase	209	217	O
)	217	218	O
genes	219	224	O
in	225	227	O
mouse	228	233	O
,	233	234	O
rat	235	238	O
,	238	239	O
and	240	243	O
Syrian	244	250	O
hamster	251	258	O
were	259	263	O
determined	264	274	O
by	275	277	O
direct	278	284	O
R	285	286	O
-	286	287	O
banding	287	294	O
FISH	295	299	O
.	299	300	O

Both	301	305	O
genes	306	311	O
were	312	316	O
colocalized	317	328	O
to	329	331	O
the	332	335	O
C	336	337	O
-	337	338	O
D	338	339	O
band	340	344	O
of	345	347	O
mouse	348	353	O
chromosome	354	364	O
9	365	366	O
,	366	367	O
the	368	371	O
proximal	372	380	O
end	381	384	O
of	385	387	O
q24	388	391	O
.	391	392	O
1	392	393	O
of	394	396	O
rat	397	400	O
chromosome	401	411	O
8	412	413	O
,	413	414	O
and	415	418	O
qa4	419	422	O
-	422	423	O
qa5	423	426	O
of	427	429	O
Syrian	430	436	O
hamster	437	444	O
chromosome	445	455	O
12	456	458	O
.	458	459	O

The	460	463	O
regions	464	471	O
in	472	474	O
the	475	478	O
mouse	479	484	O
and	485	488	O
rat	489	492	O
were	493	497	O
homologous	498	508	O
to	509	511	O
human	512	517	O
chromosome	518	528	O
11q	529	532	O
.	532	533	O

Fine	534	538	O
genetic	539	546	O
linkage	547	554	O
mapping	555	562	O
of	563	565	O
the	566	569	O
mouse	570	575	O
AT	576	578	S-Modifier
region	579	585	O
was	586	589	O
performed	590	599	O
using	600	605	O
the	606	609	O
interspecific	610	623	O
backcross	624	633	O
mice	634	638	O
.	638	639	O

Atm	640	643	O
,	643	644	O
Acat1	645	650	O
,	650	651	O
and	652	655	O
Npat	656	660	O
,	660	661	O
which	662	667	O
is	668	670	O
a	671	672	O
new	673	676	O
gene	677	681	O
isolated	682	690	O
from	691	695	O
the	696	699	O
AT	700	702	O
region	703	709	O
,	709	710	O
and	711	714	O
12	715	717	O
flanking	718	726	O
microsatellite	727	741	O
DNA	742	745	O
markers	746	753	O
were	754	758	O
examined	759	767	O
.	767	768	O

No	769	771	O
recombinations	772	786	O
were	787	791	O
found	792	797	O
among	798	803	O
the	804	807	O
Atm	808	811	O
,	811	812	O
Npat	813	817	O
,	817	818	O
Acat1	819	824	O
,	824	825	O
and	826	829	O
D9Mit6	830	836	O
loci	837	841	O
,	841	842	O
and	843	846	O
these	847	852	O
loci	853	857	O
were	858	862	O
mapped	863	869	O
2	870	871	O
.	871	872	O
0	872	873	O
cM	874	876	O
distal	877	883	O
to	884	886	O
D9Mit99	887	894	O
and	895	898	O
1	899	900	O
.	900	901	O
3	901	902	O
cM	903	905	O
proximal	906	914	O
to	915	917	O
D9Mit102	918	926	O
.	926	927	O

Comparison	928	938	O
of	939	941	O
the	942	945	O
linkage	946	953	O
map	954	957	O
of	958	960	O
mouse	961	966	O
chromosome	967	977	O
9	978	979	O
(	980	981	O
MMU9	981	985	O
)	985	986	O
and	987	990	O
that	991	995	O
of	996	998	O
human	999	1004	O
chromosome	1005	1015	O
11	1016	1018	O
(	1019	1020	O
HSA11	1020	1025	O
)	1025	1026	O
indicates	1027	1036	O
that	1037	1041	O
there	1042	1047	O
is	1048	1050	O
a	1051	1052	O
chromosomal	1053	1064	O
rearrangement	1065	1078	O
due	1079	1082	O
to	1083	1085	O
an	1086	1088	O
inversion	1089	1098	O
between	1099	1106	O
Ets1	1107	1111	O
and	1112	1115	O
Atm	1116	1119	O
-	1119	1120	O
Npat	1120	1124	O
-	1124	1125	O
Acat1	1125	1130	O
and	1131	1134	O
that	1135	1139	O
the	1140	1143	O
inversion	1144	1153	O
of	1154	1156	O
MMU9	1157	1161	O
originated	1162	1172	O
from	1173	1177	O
the	1178	1181	O
chromosomal	1182	1193	O
breakage	1194	1202	O
at	1203	1205	O
the	1206	1209	O
boundary	1210	1218	O
between	1219	1226	O
Gria4	1227	1232	O
and	1233	1236	O
Atm	1237	1240	O
-	1240	1241	O
Npat	1241	1245	O
-	1245	1246	O
Acat1	1246	1251	O
on	1252	1254	O
HSA11	1255	1260	O
.	1260	1261	O

This	1262	1266	O
type	1267	1271	O
of	1272	1274	O
inversion	1275	1284	O
appeared	1285	1293	O
to	1294	1296	O
be	1297	1299	O
conserved	1300	1309	O
in	1310	1312	O
the	1313	1316	O
three	1317	1322	O
rodent	1323	1329	O
species	1330	1337	O
,	1337	1338	O
mouse	1339	1344	O
,	1344	1345	O
rat	1346	1349	O
,	1349	1350	O
and	1351	1354	O
Syrian	1355	1361	O
hamster	1362	1369	O
,	1369	1370	O
using	1371	1376	O
additional	1377	1387	O
comparative	1388	1399	O
mapping	1400	1407	O
data	1408	1412	O
with	1413	1417	O
the	1418	1421	O
Rck	1422	1425	O
gene	1426	1430	O
.	1430	1431	O

# doc_id = 8828602
Gene	0	4	O
therapy	5	12	O
for	13	16	O
phenylketonuria	17	32	S-SpecificDisease
.	32	33	O

Classical	34	43	O
phenylketonuria	44	59	S-SpecificDisease
(	60	61	O
PKU	61	64	S-SpecificDisease
)	64	65	O
is	66	68	O
an	69	71	O
autosomal	72	81	B-DiseaseClass
recessive	82	91	I-DiseaseClass
disorder	92	100	E-DiseaseClass
caused	101	107	O
by	108	110	O
a	111	112	O
deficiency	113	123	B-SpecificDisease
of	124	126	I-SpecificDisease
hepatic	127	134	I-SpecificDisease
phenylalanine	135	148	I-SpecificDisease
hydroxylase	149	160	E-SpecificDisease
(	161	162	O
PAH	162	165	O
).	165	167	O

Limitations	168	179	O
of	180	182	O
the	183	186	O
current	187	194	O
dietary	195	202	O
treatment	203	212	O
for	213	216	O
PKU	217	220	S-SpecificDisease
have	221	225	O
led	226	229	O
to	230	232	O
the	233	236	O
development	237	248	O
of	249	251	O
potential	252	261	O
treatments	262	272	O
based	273	278	O
on	279	281	O
somatic	282	289	O
gene	290	294	O
transfer	295	303	O
.	303	304	O

Three	305	310	O
different	311	320	O
vector	321	327	O
systems	328	335	O
have	336	340	O
been	341	345	O
examined	346	354	O
.	354	355	O

Vectors	356	363	O
derived	364	371	O
from	372	376	O
a	377	378	O
recombinant	379	390	O
retrovirus	391	401	O
or	402	404	O
a	405	406	O
DNA	407	410	O
/	410	411	O
protein	411	418	O
complex	419	426	O
can	427	430	O
efficiently	431	442	O
transduce	443	452	O
the	453	456	O
PAH	457	460	O
cDNA	461	465	O
into	466	470	O
PAH	471	474	B-Modifier
-	474	475	I-Modifier
deficient	475	484	E-Modifier
hepatocytes	485	496	O
in	497	499	O
vitro	500	505	O
,	505	506	O
but	507	510	O
the	511	514	O
application	515	526	O
of	527	529	O
these	530	535	O
vector	536	542	O
systems	543	550	O
is	551	553	O
presently	554	563	O
limited	564	571	O
by	572	574	O
their	575	580	O
low	581	584	O
transduction	585	597	O
efficiency	598	608	O
in	609	611	O
vivo	612	616	O
.	616	617	O

In	618	620	O
contrast	621	629	O
,	629	630	O
a	631	632	O
vector	633	639	O
derived	640	647	O
from	648	652	O
a	653	654	O
recombinant	655	666	O
adenovirus	667	677	O
can	678	681	O
restore	682	689	O
10	690	692	O
%-	692	694	O
80	694	696	O
%	696	697	O
of	698	700	O
normal	701	707	O
hepatic	708	715	O
PAH	716	719	O
activity	720	728	O
into	729	733	O
PAH	734	737	B-Modifier
-	737	738	I-Modifier
deficient	738	747	E-Modifier
mice	748	752	O
,	752	753	O
which	754	759	O
completely	760	770	O
normalizes	771	781	O
serum	782	787	O
phenylalanine	788	801	O
levels	802	808	O
.	808	809	O

This	810	814	O
treatment	815	824	O
is	825	827	O
transient	828	837	O
and	838	841	O
cannot	842	848	O
be	849	851	O
effectively	852	863	O
re	864	866	O
-	866	867	O
administered	867	879	O
due	880	883	O
to	884	886	O
the	887	890	O
presence	891	899	O
of	900	902	O
neutralizing	903	915	O
antibodies	916	926	O
directed	927	935	O
against	936	943	O
the	944	947	O
recombinant	948	959	O
adenoviral	960	970	O
vector	971	977	O
.	977	978	O

However	979	986	O
,	986	987	O
these	988	993	O
findings	994	1002	O
suggest	1003	1010	O
that	1011	1015	O
PKU	1016	1019	S-SpecificDisease
can	1020	1023	O
be	1024	1026	O
completely	1027	1037	O
corrected	1038	1047	O
by	1048	1050	O
somatic	1051	1058	O
gene	1059	1063	O
therapy	1064	1071	O
,	1071	1072	O
and	1073	1076	O
provide	1077	1084	O
some	1085	1089	O
direction	1090	1099	O
for	1100	1103	O
the	1104	1107	O
future	1108	1114	O
development	1115	1126	O
of	1127	1129	O
adenoviral	1130	1140	O
vectors	1141	1148	O
.	1148	1149	O

# doc_id = 8944023
Identification	0	14	O
of	15	17	O
a	18	19	O
RING	20	24	O
protein	25	32	O
that	33	37	O
can	38	41	O
interact	42	50	O
in	51	53	O
vivo	54	58	O
with	59	63	O
the	64	67	O
BRCA1	68	73	O
gene	74	78	O
product	79	86	O
.	86	87	O

The	88	91	O
hereditary	92	102	B-Modifier
breast	103	109	I-Modifier
and	110	113	I-Modifier
ovarian	114	121	I-Modifier
cancer	122	128	E-Modifier
gene	129	133	O
,	133	134	O
BRCA1	135	140	O
,	140	141	O
encodes	142	149	O
a	150	151	O
large	152	157	O
polypeptide	158	169	O
that	170	174	O
contains	175	183	O
the	184	187	O
cysteine	188	196	O
-	196	197	O
rich	197	201	O
RING	202	206	O
motif	207	212	O
,	212	213	O
a	214	215	O
zinc	216	220	O
-	220	221	O
binding	221	228	O
domain	229	235	O
found	236	241	O
in	242	244	O
a	245	246	O
variety	247	254	O
of	255	257	O
regulatory	258	268	O
proteins	269	277	O
.	277	278	O

Here	279	283	O
we	284	286	O
describe	287	295	O
a	296	297	O
novel	298	303	O
protein	304	311	O
that	312	316	O
interacts	317	326	O
in	327	329	O
vivo	330	334	O
with	335	339	O
the	340	343	O
N	344	345	O
-	345	346	O
terminal	346	354	O
region	355	361	O
of	362	364	O
BRCA1	365	370	O
.	370	371	O

This	372	376	O
BRCA1	377	382	O
-	382	383	O
associated	383	393	O
RING	394	398	O
domain	399	405	O
(	406	407	O
BARD1	407	412	O
)	412	413	O
protein	414	421	O
contains	422	430	O
an	431	433	O
N	434	435	O
-	435	436	O
terminal	436	444	O
RING	445	449	O
motif	450	455	O
,	455	456	O
three	457	462	O
tandem	463	469	O
ankyrin	470	477	O
repeats	478	485	O
,	485	486	O
and	487	490	O
a	491	492	O
C	493	494	O
-	494	495	O
terminal	495	503	O
sequence	504	512	O
with	513	517	O
significant	518	529	O
homology	530	538	O
to	539	541	O
the	542	545	O
phylogenetically	546	562	O
conserved	563	572	O
BRCT	573	577	O
domains	578	585	O
that	586	590	O
lie	591	594	O
near	595	599	O
the	600	603	O
C	604	605	O
terminus	606	614	O
of	615	617	O
BRCA1	618	623	O
.	623	624	O

The	625	628	O
BARD1	629	634	O
/	634	635	O
BRCA1	635	640	O
interaction	641	652	O
is	653	655	O
disrupted	656	665	O
by	666	668	O
BRCA1	669	674	O
missense	675	683	O
mutations	684	693	O
that	694	698	O
segregate	699	708	O
with	709	713	O
breast	714	720	B-Modifier
cancer	721	727	E-Modifier
susceptibility	728	742	O
,	742	743	O
indicating	744	754	O
that	755	759	O
BARD1	760	765	O
may	766	769	O
be	770	772	O
involved	773	781	O
in	782	784	O
mediating	785	794	O
tumour	795	801	S-Modifier
suppression	802	813	O
by	814	816	O
BRCA1	817	822	O
.	822	823	O

# doc_id = 8675707
Increased	0	9	O
coronary	10	18	B-SpecificDisease
heart	19	24	I-SpecificDisease
disease	25	32	E-SpecificDisease
in	33	35	O
Japanese	36	44	O
-	44	45	O
American	45	53	O
men	54	57	O
with	58	62	O
mutation	63	71	O
in	72	74	O
the	75	78	O
cholesteryl	79	90	O
ester	91	96	O
transfer	97	105	O
protein	106	113	O
gene	114	118	O
despite	119	126	O
increased	127	136	O
HDL	137	140	O
levels	141	147	O
.	147	148	O

Plasma	149	155	O
high	156	160	O
density	161	168	O
lipoprotein	169	180	O
(	181	182	O
HDL	182	185	O
)	185	186	O
levels	187	193	O
are	194	197	O
strongly	198	206	O
genetically	207	218	O
determined	219	229	O
and	230	233	O
show	234	238	O
a	239	240	O
general	241	248	O
inverse	249	256	O
relationship	257	269	O
with	270	274	O
coronary	275	283	B-SpecificDisease
heart	284	289	I-SpecificDisease
disease	290	297	E-SpecificDisease
(	298	299	O
CHD	299	302	S-SpecificDisease
).	302	304	O

The	305	308	O
cholesteryl	309	320	O
ester	321	326	O
transfer	327	335	O
protein	336	343	O
(	344	345	O
CETP	345	349	O
)	349	350	O
mediates	351	359	O
the	360	363	O
transfer	364	372	O
of	373	375	O
cholesteryl	376	387	O
esters	388	394	O
from	395	399	O
HDL	400	403	O
to	404	406	O
other	407	412	O
lipoproteins	413	425	O
and	426	429	O
is	430	432	O
a	433	434	O
key	435	438	O
participant	439	450	O
in	451	453	O
the	454	457	O
reverse	458	465	O
transport	466	475	O
of	476	478	O
cholesterol	479	490	O
from	491	495	O
the	496	499	O
periphery	500	509	O
to	510	512	O
the	513	516	O
liver	517	522	O
.	522	523	O

A	524	525	O
high	526	530	O
prevalence	531	541	O
of	542	544	O
two	545	548	O
different	549	558	O
CETP	559	563	O
gene	564	568	O
mutations	569	578	O
(	579	580	O
D442G	580	585	O
,	585	586	O
5	587	588	O
.	588	589	O
1	589	590	O
%;	590	592	O
intron	593	599	O
14G	600	603	O
:	603	604	O
A	604	605	O
,	605	606	O
0	607	608	O
.	608	609	O
5	609	610	O
%),	610	613	O
was	614	617	O
found	618	623	O
in	624	626	O
3	627	628	O
,	628	629	O
469	629	632	O
men	633	636	O
of	637	639	O
Japanese	640	648	O
ancestry	649	657	O
in	658	660	O
the	661	664	O
Honolulu	665	673	O
Heart	674	679	O
Program	680	687	O
and	688	691	O
mutations	692	701	O
were	702	706	O
associated	707	717	O
with	718	722	O
decreased	723	732	O
CETP	733	737	O
(-	738	740	O
35	740	742	O
%)	742	744	O
and	745	748	O
increased	749	758	O
HDL	759	762	O
chol	763	767	O
levels	768	774	O
(+	775	777	O
10	777	779	O
%	779	780	O
for	781	784	O
D442G	785	790	O
).	790	792	O

However	793	800	O
,	800	801	O
the	802	805	O
overall	806	813	O
prevalence	814	824	O
of	825	827	O
definite	828	836	O
CHD	837	840	S-SpecificDisease
was	841	844	O
21	845	847	O
%	847	848	O
in	849	851	O
men	852	855	O
with	856	860	O
mutations	861	870	O
and	871	874	O
16	875	877	O
%	877	878	O
in	879	881	O
men	882	885	O
without	886	893	O
mutations	894	903	O
.	903	904	O

The	905	908	O
relative	909	917	O
risk	918	922	O
(	923	924	O
RR	924	926	O
)	926	927	O
of	928	930	O
CHD	931	934	S-SpecificDisease
was	935	938	O
1	939	940	O
.	940	941	O
43	941	943	O
in	944	946	O
men	947	950	O
with	951	955	O
mutations	956	965	O
(	966	967	O
P	967	968	O
<	969	970	O
.	971	972	O
05	972	974	O
);	974	976	O
after	977	982	O
adjustment	983	993	O
for	994	997	O
CHD	998	1001	S-Modifier
risk	1002	1006	O
factors	1007	1014	O
,	1014	1015	O
the	1016	1019	O
RR	1020	1022	O
was	1023	1026	O
1	1027	1028	O
.	1028	1029	O
55	1029	1031	O
(	1032	1033	O
P	1033	1034	O
=	1035	1036	O
.	1037	1038	O
02	1038	1040	O
);	1040	1042	O
after	1043	1048	O
additional	1049	1059	O
adjustment	1060	1070	O
for	1071	1074	O
HDL	1075	1078	O
levels	1079	1085	O
,	1085	1086	O
the	1087	1090	O
RR	1091	1093	O
was	1094	1097	O
1	1098	1099	O
.	1099	1100	O
68	1100	1102	O
(	1103	1104	O
P	1104	1105	O
=	1106	1107	O
.	1108	1109	O
008	1109	1112	O
).	1112	1114	O

Similar	1115	1122	O
RR	1123	1125	O
values	1126	1132	O
were	1133	1137	O
obtained	1138	1146	O
for	1147	1150	O
the	1151	1154	O
D442G	1155	1160	O
mutation	1161	1169	O
alone	1170	1175	O
.	1175	1176	O

Increased	1177	1186	O
CHD	1187	1190	S-SpecificDisease
in	1191	1193	O
men	1194	1197	O
with	1198	1202	O
mutations	1203	1212	O
was	1213	1216	O
primarily	1217	1226	O
observed	1227	1235	O
for	1236	1239	O
HDL	1240	1243	O
chol	1244	1248	O
41	1249	1251	O
-	1251	1252	O
60	1252	1254	O
mg	1255	1257	O
/	1257	1258	O
dl	1258	1260	O
;	1260	1261	O
for	1262	1265	O
HDL	1266	1269	O
chol	1270	1274	O
>	1275	1276	O
60	1277	1279	O
mg	1280	1282	O
/	1282	1283	O
dl	1283	1285	O
men	1286	1289	O
with	1290	1294	O
and	1295	1298	O
without	1299	1306	O
mutations	1307	1316	O
had	1317	1320	O
low	1321	1324	O
CHD	1325	1328	S-SpecificDisease
prevalence	1329	1339	O
.	1339	1340	O

Thus	1341	1345	O
,	1345	1346	O
genetic	1347	1354	O
CETP	1355	1359	B-SpecificDisease
deficiency	1360	1370	E-SpecificDisease
appears	1371	1378	O
to	1379	1381	O
be	1382	1384	O
an	1385	1387	O
independent	1388	1399	O
risk	1400	1404	O
factor	1405	1411	O
for	1412	1415	O
CHD	1416	1419	S-SpecificDisease
,	1419	1420	O
primarily	1421	1430	O
due	1431	1434	O
to	1435	1437	O
increased	1438	1447	O
CHD	1448	1451	S-Modifier
prevalence	1452	1462	O
in	1463	1465	O
men	1466	1469	O
with	1470	1474	O
the	1475	1478	O
D442G	1479	1484	O
mutation	1485	1493	O
and	1494	1497	O
HDL	1498	1501	O
cholesterol	1502	1513	O
between	1514	1521	O
41	1522	1524	O
and	1525	1528	O
60	1529	1531	O
mg	1532	1534	O
/	1534	1535	O
dl	1535	1537	O
.	1537	1538	O

The	1539	1542	O
findings	1543	1551	O
suggest	1552	1559	O
that	1560	1564	O
both	1565	1569	O
HDL	1570	1573	O
concentration	1574	1587	O
and	1588	1591	O
the	1592	1595	O
dynamics	1596	1604	O
of	1605	1607	O
cholesterol	1608	1619	O
transport	1620	1629	O
through	1630	1637	O
HDL	1638	1641	O
(	1642	1643	O
i	1643	1644	O
.	1644	1645	O
e	1645	1646	O
.,	1646	1648	O
reverse	1649	1656	O
cholesterol	1657	1668	O
transport	1669	1678	O
)	1678	1679	O
determine	1680	1689	O
the	1690	1693	O
anti	1694	1698	O
-	1698	1699	O
atherogenicity	1699	1713	O
of	1714	1716	O
the	1717	1720	O
HDL	1721	1724	O
fraction	1725	1733	O
.	1733	1734	O

# doc_id = 8968760
Ataxia	0	6	B-SpecificDisease
-	6	7	I-SpecificDisease
telangiectasia	7	21	E-SpecificDisease
:	21	22	O
founder	23	30	O
effect	31	37	O
among	38	43	O
north	44	49	O
African	50	57	O
Jews	58	62	O
.	62	63	O

The	64	67	O
ATM	68	71	O
gene	72	76	O
is	77	79	O
responsible	80	91	O
for	92	95	O
the	96	99	O
autosomal	100	109	B-DiseaseClass
recessive	110	119	I-DiseaseClass
disorder	120	128	E-DiseaseClass
ataxia	129	135	B-SpecificDisease
-	135	136	I-SpecificDisease
telangiectasia	136	150	E-SpecificDisease
(	151	152	O
A	152	153	B-SpecificDisease
-	153	154	I-SpecificDisease
T	154	155	E-SpecificDisease
),	155	157	O
characterized	158	171	O
by	172	174	O
cerebellar	175	185	B-DiseaseClass
degeneration	186	198	E-DiseaseClass
,	198	199	O
immunodeficiency	200	216	S-DiseaseClass
and	217	220	O
cancer	221	227	B-DiseaseClass
predisposition	228	242	E-DiseaseClass
.	242	243	O

A	244	245	B-Modifier
-	245	246	I-Modifier
T	246	247	E-Modifier
carriers	248	256	O
were	257	261	O
reported	262	270	O
to	271	273	O
be	274	276	O
moderately	277	287	O
cancer	288	294	B-DiseaseClass
-	294	295	I-DiseaseClass
prone	295	300	E-DiseaseClass
.	300	301	O

A	302	303	O
wide	304	308	O
variety	309	316	O
of	317	319	O
A	320	321	B-Modifier
-	321	322	I-Modifier
T	322	323	E-Modifier
mutations	324	333	O
,	333	334	O
most	335	339	O
of	340	342	O
which	343	348	O
are	349	352	O
unique	353	359	O
to	360	362	O
single	363	369	O
families	370	378	O
,	378	379	O
were	380	384	O
identified	385	395	O
in	396	398	O
various	399	406	O
ethnic	407	413	O
groups	414	420	O
,	420	421	O
precluding	422	432	O
carrier	433	440	O
screening	441	450	O
with	451	455	O
mutation	456	464	O
-	464	465	O
specific	465	473	O
assays	474	480	O
.	480	481	O

However	482	489	O
,	489	490	O
a	491	492	O
single	493	499	O
mutation	500	508	O
was	509	512	O
observed	513	521	O
in	522	524	O
32	525	527	O
/	527	528	O
33	528	530	O
defective	531	540	O
ATM	541	544	O
alleles	545	552	O
in	553	555	O
Jewish	556	562	O
A	563	564	B-Modifier
-	564	565	I-Modifier
T	565	566	E-Modifier
families	567	575	O
of	576	578	O
North	579	584	O
African	585	592	O
origin	593	599	O
,	599	600	O
coming	601	607	O
from	608	612	O
various	613	620	O
regions	621	628	O
of	629	631	O
Morocco	632	639	O
and	640	643	O
Tunisia	644	651	O
.	651	652	O

This	653	657	O
mutation	658	666	O
,	666	667	O
103C	668	672	O
-->	672	675	O
T	675	676	O
,	676	677	O
results	678	685	O
in	686	688	O
a	689	690	O
stop	691	695	O
codon	696	701	O
at	702	704	O
position	705	713	O
35	714	716	O
of	717	719	O
the	720	723	O
ATM	724	727	O
protein	728	735	O
.	735	736	O

In	737	739	O
keeping	740	747	O
with	748	752	O
the	753	756	O
nature	757	763	O
of	764	766	O
this	767	771	O
mutation	772	780	O
,	780	781	O
various	782	789	O
antibodies	790	800	O
directed	801	809	O
against	810	817	O
the	818	821	O
ATM	822	825	O
protein	826	833	O
failed	834	840	O
to	841	843	O
defect	844	850	O
this	851	855	O
protein	856	863	O
in	864	866	O
patient	867	874	O
cells	875	880	O
.	880	881	O

A	882	883	O
rapid	884	889	O
carrier	890	897	O
detection	898	907	O
assay	908	913	O
detected	914	922	O
this	923	927	O
mutation	928	936	O
in	937	939	O
three	940	945	O
out	946	949	O
of	950	952	O
488	953	956	O
ATM	957	960	O
alleles	961	968	O
of	969	971	O
Jewish	972	978	O
Moroccan	979	987	O
or	988	990	O
Tunisian	991	999	O
origin	1000	1006	O
.	1006	1007	O

This	1008	1012	O
founder	1013	1020	O
effect	1021	1027	O
provides	1028	1036	O
a	1037	1038	O
unique	1039	1045	O
opportunity	1046	1057	O
for	1058	1061	O
population	1062	1072	O
-	1072	1073	O
based	1073	1078	O
screening	1079	1088	O
for	1089	1092	O
A	1093	1094	B-Modifier
-	1094	1095	I-Modifier
T	1095	1096	E-Modifier
carriers	1097	1105	O
in	1106	1108	O
a	1109	1110	O
large	1111	1116	O
Jewish	1117	1123	O
community	1124	1133	O
.	1133	1134	O

